{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:19:19Z","timestamp":1778692759991,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00108-021-00987-1","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T14:04:07Z","timestamp":1615817047000},"page":"513-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gicht","Gout"],"prefix":"10.1007","volume":"62","author":[{"given":"A. K.","family":"Tausche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"987_CR1","doi-asserted-by":"publisher","first-page":"DocEV.05","DOI":"10.3205\/18dgrh054","volume":"10","author":"AK Tausche","year":"2019","unstructured":"Tausche\u00a0AK, Schmedt\u00a0N, Karra\u00a0R, Petersen\u00a0G, Sch\u00f6nfelder\u00a0T, Kiltz\u00a0U (2019) Prevalence and incidence of gout in Germany. Ger Med Sci 10:DocEV.5. https:\/\/doi.org\/10.3205\/18dgrh054","journal-title":"Ger Med Sci"},{"issue":"4","key":"987_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.rdc.2019.08.001","volume":"45","author":"F Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz\u00a0F, Dalbeth\u00a0N (2019) Gout. Rheum Dis Clin North Am 45(4):583\u2013591","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"987_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s10067-019-04520-6","volume":"38","author":"IJM Disveld","year":"2019","unstructured":"Disveld\u00a0IJM, Zoakman\u00a0S, Jansen\u00a0TLTA et al (2019) Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and\/or high serum uric acid levels: a\u00a0prospective cohort study. Clin Rheumatol 38(5):1385\u20131391","journal-title":"Clin Rheumatol"},{"key":"987_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30221-6","author":"R Hansildaar","year":"2020","unstructured":"Hansildaar\u00a0R, Vedder\u00a0D, Baniaamam\u00a0M, Tausche\u00a0AK, Gerritsen\u00a0M, Nurmohamed\u00a0MT (2020) Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(20)30221-6","journal-title":"Lancet Rheumatol"},{"issue":"14","key":"987_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1055\/s-0028-1103816","volume":"92","author":"N Z\u00f6llner","year":"1967","unstructured":"Z\u00f6llner\u00a0N, Schattenkirchner\u00a0M (1967) Allopurinol in the treatment of gout and uric acid nephrolithiasis. Dtsch Med Wochenschr 92(14):654\u2013660","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"987_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette\u00a0P, Doherty\u00a0M, Pascual\u00a0E et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"987_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00393-016-0249-1","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz\u00a0U, Alten\u00a0R, Fleck\u00a0M et al (2017) Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector: S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF. Z\u00a0Rheumatol 76(2):118\u2013124","journal-title":"Z Rheumatol"},{"issue":"4","key":"987_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/rheumatology\/keu378","volume":"54","author":"LB Kienhorst","year":"2015","unstructured":"Kienhorst\u00a0LB, Janssens\u00a0HJ, Fransen\u00a0J, Janssen\u00a0M (2015) The validation of a\u00a0diagnostic rule for gout without joint fluid analysis: a\u00a0prospective study. Rheumatology 54(4):609\u2013614","journal-title":"Rheumatology"},{"key":"987_CR9","first-page":"1","volume-title":"Klinik der Gegenwart","author":"HE Schr\u00f6der","year":"1993","unstructured":"Schr\u00f6der\u00a0HE (1993) Gicht. In: Hartmann\u00a0F, Philipp\u00a0T (Hrsg) Klinik der Gegenwart. Urban & Schwarzenberg, M\u00fcnchen, S\u00a01\u201348"},{"issue":"12","key":"987_CR10","first-page":"1207","volume":"36","author":"W Gr\u00f6bner","year":"1995","unstructured":"Gr\u00f6bner\u00a0W, Z\u00f6llner\u00a0N (1995) Hyperuricemia. Internist 36(12):1207\u20131221","journal-title":"Internist"},{"issue":"4","key":"987_CR11","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.semarthrit.2016.08.003","volume":"46","author":"C Petsch","year":"2017","unstructured":"Petsch\u00a0C, Araujo\u00a0E, Hueber\u00a0A, Schett\u00a0G, Manger\u00a0B, Rech\u00a0J (2017) Gout mimicking rheumatoid arthritis. Semin Arthritis Rheum 46(4):e15","journal-title":"Semin Arthritis Rheum"},{"issue":"16","key":"987_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1055\/a-0504-5684","volume":"143","author":"M Reuss-Borst","year":"2018","unstructured":"Reuss-Borst\u00a0M, Tausche\u00a0AK (2018) Update on Gout and Calcium pyrophosphate deposition (CPPD). Dtsch Med Wochenschr 143(16):1157\u20131166","journal-title":"Dtsch Med Wochenschr"},{"issue":"3","key":"987_CR13","first-page":"e7196","volume":"12","author":"B Toms","year":"2020","unstructured":"Toms\u00a0B (2020) Driveline sepsis presenting as gout. Cureus 12(3):e7196","journal-title":"Cureus"},{"issue":"3S","key":"987_CR14","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2020.04.007","volume":"50","author":"RT Keenan","year":"2020","unstructured":"Keenan\u00a0RT (2020) The biology of urate. Semin Arthritis Rheum 50(3S):S2\u2013S10","journal-title":"Semin Arthritis Rheum"},{"issue":"7081","key":"987_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon\u00a0F, P\u00e9trilli\u00a0V, Mayor\u00a0A, Tardivel\u00a0A, Tschopp\u00a0J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237\u2013241","journal-title":"Nature"},{"key":"987_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217342","author":"F Renaudin","year":"2020","unstructured":"Renaudin\u00a0F, Orliaguet\u00a0L, Castelli\u00a0F et al (2020) Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1\u03b2 activation on macrophages. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217342","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"987_CR17","doi-asserted-by":"publisher","first-page":"e000046","DOI":"10.1136\/rmdopen-2015-000046","volume":"1","author":"G Schett","year":"2015","unstructured":"Schett\u00a0G, Schauer\u00a0C, Hoffmann\u00a0M, Herrmann\u00a0M (2015) Why does the gout attack stop? A roadmap for the immune pathogenesis of gout. RMD Open 1(Suppl 1):e46","journal-title":"RMD Open"},{"issue":"10","key":"987_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi\u00a0T, Jansen\u00a0TL, Dalbeth\u00a0N et\u00a0al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u20131798","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"987_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette\u00a0P, Doherty\u00a0M, Pascual\u00a0E et al (2020) 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79(1):31\u201338","journal-title":"Ann Rheum Dis"},{"key":"987_CR20","first-page":"34","volume-title":"Gicht \u2013 neue Aspekte zur Pathogenese, Diagnostik und Therapie","author":"W Schmidt","year":"2014","unstructured":"Schmidt\u00a0W (2014) Bildgebung bei Gicht. In: Tausche\u00a0AK, Aringer\u00a0M (Hrsg) Gicht \u2013 neue Aspekte zur Pathogenese, Diagnostik und Therapie. UNI-MED, Bremen, S 34\u201336"},{"issue":"5","key":"987_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11926-020-0890-1","volume":"22","author":"T Pascart","year":"2020","unstructured":"Pascart\u00a0T, Iagnocco\u00a0A (2020) Utility of ultrasound and dual energy CT in crystal disease diagnosis and management. Curr Rheumatol Rep 22(5):15. https:\/\/doi.org\/10.1007\/s11926-020-0890-1","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"987_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/RHU.0b013e31829cde53","volume":"19","author":"AK Tausche","year":"2013","unstructured":"Tausche\u00a0AK, Gehrisch\u00a0S, Panzner\u00a0I et al (2013) A 3\u2011day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals. J\u00a0Clin Rheumatol 19(5):241\u2013245","journal-title":"J Clin Rheumatol"},{"key":"987_CR23","unstructured":"https:\/\/www.drugbank.ca\/drugs\/DB01394. Zugegriffen: 02 Dec 2020"},{"issue":"10156","key":"987_CR24","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty\u00a0M, Jenkins\u00a0W, Richardson\u00a0H et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a\u00a0treat-to-target urate-lowering strategy versus usual care for gout: a\u00a0randomised controlled trial. Lancet 392(10156):1403\u20131412","journal-title":"Lancet"},{"issue":"5","key":"987_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00108-020-00766-4","volume":"61","author":"R Alten","year":"2020","unstructured":"Alten\u00a0R, Mischkewitz\u00a0M, Nitschmann\u00a0S (2020) Febuxostat or allopurinol in patients with gout : cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES). Internist 61(5):530\u2013532","journal-title":"Internist"},{"key":"987_CR26","doi-asserted-by":"publisher","first-page":"212581","DOI":"10.7573\/dic.212581","volume":"8","author":"F P\u00e9rez-Ruiz","year":"2019","unstructured":"P\u00e9rez-Ruiz\u00a0F, Jansen\u00a0T, Tausche\u00a0AK, Ju\u00e1rez-Campo\u00a0M, Gurunath\u00a0RK, Richette\u00a0P (2019) Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context 8:212581","journal-title":"Drugs Context"},{"key":"987_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.07.006","author":"C Borghi","year":"2020","unstructured":"Borghi\u00a0C, Agabiti-Rosei\u00a0E, Johnson\u00a0RJ, Kielstein\u00a0JT, Lurbe\u00a0E, Mancia\u00a0G, Redon\u00a0J, Stack\u00a0AG, Tsioufis\u00a0KP (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2020.07.006","journal-title":"Eur J Intern Med"},{"issue":"7","key":"987_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00108-020-00768-2","volume":"61","author":"R Klingenberg","year":"2020","unstructured":"Klingenberg\u00a0R, Nitschmann\u00a0S (2020) Colchicine treatment after myocardial infarction: colchicine Cardiovascular Outcomes Trial (COLCOT). Internist 61(7):766\u2013769","journal-title":"Internist"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-00987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-00987-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-00987-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T14:05:28Z","timestamp":1619532328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-00987-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-00987-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"9 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>A.-K.\u00a0Tausche<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: AstraZeneca, Menarini f\u00fcr Durchf\u00fchrung von klinischen Phase-III-Studien zur Gicht. \u2013\u00a0Vortragshonorare, Kosten\u00fcbernahme (Kongressteilnahme): Berlin-Chemie Menarini, AstraZeneca, Novartis, Gr\u00fcnenthal.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Rheumatologin, Leiterin Studienambulanz Rheumatologie, Medizinische Klinik\u00a0III, Universit\u00e4tsklinikum Carl Gustav Carus, Technische Universit\u00e4t Dresden, Mitautorin der S2e-Leitlinie \u201eGichtarthritis\u201c der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh), der Leitlinien der European League Against Rheumatism (EULAR) zur Gicht sowie der \u201egout classification criteria\u201c von American College of Rheumatology (ACR) und EULAR, | Mitgliedschaft: DGRh.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}